Background Valve-in-valve (ViV) procedures for degenerated bioprostheses are an
alternative for the standard of care in an aging population. Several reports showed that the …

Bioprosthetic surgical heart valves (SHVs) tend to degenerate with time, and valve re-
operation carries substantial risks. Transcatheter heart valve (THV) implantation into a …

Valve-in-valve implantation for degenerated surgical bioprosthetic valves is becoming an
increasingly accepted approach in selected high-risk patients. In the past, valve-in-valve …

OBJECTIVES: This study evaluates reinterventions for degenerated stentless aortic
xenografts. METHODS: Between 2010 and 2015, 52 consecutive patients (age 72.3±9.7 …

Objective: The ideal substitute for the diseased aortic valve is yet to be found. For the
assessment and comparison of the midterm results after aortic valve replacement with three …

The use of bioprosthetic valves for treating patients with severe valve disease has increased
over the last 2 decades, and, as a consequence, a growing number of patients with failing …

Objectives Transcatheter valve-in-valve implantation (ViV) is emerging as a novel treatment
option for patients with deteriorated bioprostheses. We report our cumulative experience …

Replacement of the diseased aortic valve represents one of the triumphs of cardiac surgery;
however, the perfect valve substitute continues to elude surgeons after almost four decades …

Objectives: The valve‐in‐valve (VIV) technique is an emerging therapeutic option for
patients with failure of previously implanted xenografts. We describe a balloon‐expandable …

BACKGROUND: The reoperative risk for degenerated aortic valve xenografts may be
increased in elderly patients with comorbidities. We evaluated the off-pump beating heart …